Dosimetry-guided radioiodine therapy of hyperthyroidism: long-term experience and implications for guidelines.

Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8201017 Publication Model: Print Cited Medium: Internet ISSN: 1473-5628 (Electronic) Linking ISSN: 01433636 NLM ISO Abbreviation: Nucl Med Commun

Publication: London : Lippincott Williams & Wilkins
Original Publication: London : Chapman and Hall in association with the British Nuclear Medicine Society, c1980-

Iodine Radioisotopes*/therapeutic use ; Hyperthyroidism*/radiotherapy ; Radiometry*; Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Adult ; Practice Guidelines as Topic ; Aged ; Follow-Up Studies ; Graves Disease/radiotherapy ; Time Factors ; Young Adult ; Adolescent

Background: Long-term follow-up after radioactive iodine therapy (RIT) for Graves' disease and toxic thyroid autonomy is incompletely addressed by current guidelines. We retrospectively analyzed the clinical course of 1233 out of 1728 consecutive Graves' disease (n = 536) and thyroid autonomy (n = 1192) patients after dosimetry-guided RIT to optimize follow-up.
Methods: Patients were referred between 1990 and 2018; follow-up was monitored according to available electronic registers with medical reports, including autopsies from 9 hospitals and 10 residential care homes.
Results: In total, 495/1728 cases were censored because of incomplete 6-month follow-up data. The conversion rates to hypothyroidism in Graves' disease and different forms of thyroid autonomy can be deconvoluted into two follow-up periods: first year after RIT and afterward. The conversion rate in Graves' disease was significantly higher than that in all thyroid autonomy subgroups during the first year but almost identical afterwards. Thyroxine substitution started between 10 and 7900 days after RIT at thyroid stimulating hormone between 0.11 and 177 µU/ml.
Conclusions: We advise earlier (2-3 weeks) first follow-up checks after RIT in all Graves' disease patients and thyroid autonomy under antithyroid drugs (ATD) and re-checks every 2-4 weeks until conversion to hypothyroidism during the first year. The first check in thyroid autonomy without ATD should be after 3-4 weeks with re-checks every 4-6 weeks. After 1 year, both groups can be re-checked every 4-6 months over the next 5 years. The success rate of RIT in thyroid autonomyincreases with age but the history of RIT is rapidly lost during follow-up.
(Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)

Vidal-Trecan GM, Stahl JE, Durand-Zaleski I. Managing toxic thyroid adenoma: a cost-effectiveness analysis. Eur J Endocrinol 2002; 146:283–294.
Peacey SR, Kumar S, Wright D, King R. The follow-up of radioiodine-treated hyperthyroid patients: should thyroid function be monitored more frequently? J Endocrinol Invest 2012; 35:82–86.
Thyroid disease: assessment and management: NICE guideline. 2019. https://www.nice.org.uk/guidance/ng145 . [Accessed 9 October 2020].
Sjölin G, Holmberg M, Törring O, Byström K, Khamisi S, de Laval D, et al. The long-term outcome of treatment for Graves’ hyperthyroidism. Thyroid 2019; 29:1545–1557.
Wiersinga WW. Graves’ disease: can it be cured. Endocrinol Metab 2019; 34:29–38.
Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of graves’ hyperthyroidism. Eur Thyroid J 2018; 7:167–186.
Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, et al. AACE 2002 Medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002: 8:457–469.
Stokkel MP, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 2010; 37:2218–2228.
Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med 2012; 53:1633–1651.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26:1343–1421.
Rokni H, Sadeghi R, Moossavi Z, Treglia G, Zakavi SR. Efficacy of different protocols of radioiodine therapy for treatment of toxic nodular goiter: systematic review and meta-analysis of the literature. Int J Endocrinol Metab 2014; 12:e14424.
Smithson M, Asban A, Miller J, Chen H. Considerations for thyroidectomy as treatment for Graves disease. Clin Med Insights Endocrinol Diabetes 2019; 12:1179551419844523.
Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine–a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996; 81:2986–2993.
Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: a meta-analysis. J Surg Res 2000; 90:161–165.
Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2013; 98:3671–3677.
Bizzaro N, Bagnasco M, Tozzoli R, Brusca I, Cinquanta L, Tampoia M, et al. Choosing Wisely in autoimmunologia: le 5 Proposte del Gruppo di Studio in Autoimmunologia della SIPMeL. La Rivista Italiana Della Medicina Di Laboratorio - Italian Journal of Laboratory Medicine 2018; 4:11–19.
Kinser JA, Roesler H, Furrer T, Grütter D, Zimmermann H. Nonimmunogenic hyperthyroidism: cumulative hypothyroidism incidence after radioiodine and surgical treatment. J Nucl Med 1989; 30:1960–1965.
Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med 2002: 29 (Suppl 2):S471–S478.
Kohnen B, Schürmeyer C, Schürmeyer TH, Kress P. Surgery of benign thyroid disease by ENT/head and neck surgeons and general surgeons: 233 cases of vocal fold paralysis in 3509 patients. Eur Arch Otorhinolaryngol 2018; 275:2397–2402.
Pandev R, Kouzi A, Cherkezov G, Damyanov D. Selective or radical surgical strategy in functional autonomy of the thyroid in endemic areas. Khirurgiia (Sofiia) 2013; 2:12–14.
Sarkis LM, Norlen O, Sywak M, Delbridge L. Minimally invasive thyroid nodulectomy reduces post-operative hypothyroidism when compared with thyroid lobectomy. ANZ J Surg 2017; 87:360–363.
Lang BH, Wong CKH, Wong KP, Chu KK, Shek TWH. Effect of thyroid remnant volume on the risk of hypothyroidism after hemithyroidectomy: a prospective study. Ann Surg Oncol 2017; 24:1525–1532.
Zatelli MC, Lamartina L, Meringolo D, Arvat E, Damiani L, Grani G, et al. Thyroid nodule recurrence following lobo-isthmectomy: incidence, patient’s characteristics, and risk factors. J Endocrinol Invest 2018; 41:1469–1475.
Nygaard B, Hegedüs L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf) 1999; 50:197–202.
Kahraman D, Keller C, Schneider C, Eschner W, Sudbrock F, Schmidt M, et al. Development of hypothyroidism during long-term follow-up of patients with toxic nodular goitre after radioiodine therapy. Clin Endocrinol 2012; 76:297–303.
Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin Endocrinol (Oxf) 2005; 62:331–335.
AACE Thyroid Task Force. AACE Medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8:458–469.
Ross DS, Cooper DS, Mulder JE. Monitoring radioiodine in the treatment of hyperthyroidism. Available at: https://www.uptodate.com/contents/radioiodine-in-the-treatment-of-hyperthyroidism . UpToDate last updated: 13 August 2018.
Todorov L, Ait Boudaoud A, Pascal de Raykeer R, Radu A, Lahlou-Laforêt K, Limosin F, et al. A case of violent suicide attempt in a context of myxedema psychosis following radioiodine treatment in a patient with Graves’ disease. Case Rep Psychiatry 2019; 2019:4972760.
Er C, Sule AA. Late onset radioiodine-induced hypothyroidism presenting with psychosis 14 years after treatment: a rare case. Oxf Med Case Reports 2016; 2016:68–70.
Jbara Y, Bricker D. Rhabdomyolysis in the setting of induced hypothyroidism and statin therapy: a case report. Eur Thyroid J 2015; 4:62–64.
Jaeschke H, Eszlinger M, Lueblinghoff J, Coslovsky R, Paschke R. Prolonged inappropriate TSH suppression during hypothyroidism after thyroid ablation in a patient with nonautoimmune familial hyperthyroidism. Horm Metab Res 2011; 43:500–504.
Bogner L, Czempiel H. Approximation errors in the physical planning of radioiodine therapy of the thyroid. Nuklearmedizin 1993; 32:236–246.
Gayed I, Wendt J, Haynie T, Dhekne R, Moore W. Timing for repeated treatment of hyperthyroid disease with radioactive iodine after initial treatment failure. Clin Nucl Med 2001; 26:1–5.
Holm LE, Lundell G, Israelsson A, Dahlqvist I. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med 1982; 23:103–107.
Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 2004; 61:641–648.
Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH. Striving for euthyroidism in radioiodine therapy of Graves’ disease: a 12-year prospective, randomized, open-label blinded end point study. Thyroid 2011; 21:647–654.
Bakos B, Takács I, Nagy Z, Kósa JP, Balla B, Tóbiás B, et al. Long term efficacy of radioiodine treatment in hyperthyroidism. Exp Clin Endocrinol Diabetes 2013; 121:494–497.
Bajner Á. Radiojód-terápia pajzsmirigy-autonómiában: kezdeti eredményeink, tapasztalataink. Orv Hetil 2008; 18:839–842.
Boelaert K, Syed AA, Manji NA, Sheppard MC, Holder RL, Gough SC, Franklyn JA. Prediction of cure and risk of hypothyroidism in patients receiving I-131 for hyperthyroidism. Clin Endocrinol 2009; 70:129–138.
Filesi M, Travascio L, Montesano T, Di Nicola AD, Colandrea M, Ugolini F, et al. The relationship between 24 h/4 h radioiodine-131 uptake ratio and outcome after radioiodine therapy in 1402 patients with solitary autonomously functioning thyroid nodules. Ann Nucl Med 2009; 23:229–234.
Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 1999; 159:1364–1368.
Gómez JM, Virgili N, Soler J, Fernández M, Montaña E. Transient hypothyroidism after iodine-131 treatment of Graves’ disease. Thyroidology 1989; 1:149–152.
Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves’ disease. Am J Med 1995; 99:173–179.
Dong Q, Liu X, Wang F, Xu Y, Liang C, Du W, Gao G. Dynamic changes of TRAb and TPOAb after radioiodine therapy in Graves’ disease. Acta Endocrinol (Buchar) 2017; 13:72–76.
Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin Endocrinol (Oxf) 2005; 62:331–335.
Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001; 86:3611–3617.
Aktaş GE, Turoğlu HT, Erdil TY, İnanir S, Dede F. Long-term results of fixed high-dose I-131 treatment for toxic nodular goiter: higher euthyroidism rates in geriatric patients. Mol Imaging Radionucl Ther 2015; 24:94–99.
Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012; 33:920–980.
de Rooij A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol 2009; 161:771–777.
Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves’ hyperthyroidism. Cancer Biother Radiopharm 2005; 20:218–223.
Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. Failure of radioactive iodine in the treatment of hyperthyroidism. Ann Surg Oncol 2014; 21:4174–4180.
Dietlein M, Moka D, Dederichs B, Hunsche E, Lauterbach KW, Schicha H. Kosten-Effektivitäts-Analyse: Radioiod oder thyreostatische Medikation bei der Primärbehandlung der Immunhyperthyreose. Nuklearmedizin 1999; 38:7–14.
Hardisty CA, Jones SJ, Hedley AJ, Munro DS, Bewsher PD, Weir RD. Clinical outcome and costs of care in radioiodine treatment of hyperthyroidism. J R Coll Physicians Lond 1990; 24:36–42.
Ljunggren JG, Törring O, Wallin G, Taube A, Tallstedt L, Hamberger B, Lundell G. Quality of life aspects and costs in treatment of Graves’ hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998; 8:653–659.

0 (Iodine Radioisotopes)

Date Created: 20201109 Date Completed: 20240724 Latest Revision: 20240724

20240726

10.1097/MNM.0000000000001315

33165252